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with patients in lower classes, significantly higher AIX, VA, 
and differences to the chronological age were found. The VA, 
deduced from the noninvasively obtained AIX, is a promising 
candidate for screening programs for atherosclerosis, i.e., in 
occupational health screening programs.
Keywords Atherosclerosis screening · Augmentation 
index · Photoplethysmography · Vascular age
Introduction
Risk assessment for atherosclerosis is an important step 
in primary prevention of cardiovascular events to identify 
patients that should undergo more specific diagnostic strate-
gies and medical interventions [1]. Risk assessment mod-
els, such as the Framingham score or the European SCORE 
system, integrate several risk factors for fatal cardiovascular 
events, including hyperlipoproteinemia, hypertension, gender, 
and chronological age [2, 3]. However, they provide only a 
rough estimation of the individual risk of single person [4].
Since the spatial resolution of ultrasound probes was 
high enough to directly visualize early stages of atheroscle-
rosis, such as changes of the intima media thickness (IMT) 
in the carotid arteries, and age-dependent normal values 
had been described, individual values could be normal-
ized to the chronological age. This led to the term “vascular 
age” [5, 6]. The IMT is an independent predictor of cardio-
vascular events [7]; however, its main disadvantage is the 
need of experienced investigators and high-frequency ultra-
sound probes for accurate measurements. In consequence, 
its determination is not feasible for screening programs, 
i.e., in occupational health screening programs.
The concept of the vascular age (VA), however, has been 
adapted to the Framingham data and the European SCORE 
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system [8–11], as well as regional differences have been 
implemented into the SCORE system to increase their 
sensitivity [12, 13], but still there is a need for screening 
devices with higher predictive value.
The pulse wave velocity (PWV) and the changes in the 
pulse wave reflections, quantified as augmentation index 
(AIX), are parameters of arterial stiffness [14]. Pathologic 
values of these parameters have a prognostic value for mor-
tality and cardiovascular events in symptomatic and asymp-
tomatic patients [15–17]. In a recently published twin 
study, the age dependency of these parameters has been 
confirmed as well as the genetic influence [18]. Changes in 
the arterial stiffness are additionally the result of influences, 
such as arterial hypertension and atherosclerosis. There are 
several devices available for the noninvasive measurement 
of the PWV and AIX.
The aim of this pilot study was to measure the PWV 
and AIX with the photoplethysmography-based Vascu-
lar Explorer (Enverdis, Germany) [19] and to evaluate the 
concept of normalizing these parameters to age-dependent 
normal values, resulting in a new variation of the term vas-
cular age. This normalization should increase the predic-
tive value of these parameters concerning the presence or 
absence of atherosclerosis, i.e., in the setting of occupa-
tional health screening programs.
Methods
Patients and screening procedures
All subsequent patients, who were submitted in our 
department with suspicion for coronary heart disease for 
a heart catheterization between November 2010 and Feb-
ruary 2011, were screened and patients with known ath-
erosclerotic disease at any site excluded. After written 
informed consent, the screening for atherosclerosis was 
performed with duplex ultrasound examination of the 
extracranial cerebral arteries, a measurement of the ankle 
brachial index (ABI) in rest and after standardized exercise 
test and angiography of the coronary arteries. Arterioscle-
rotic disease was quantified in the extracerebral and coro-
nary arteries as no atherosclerosis (0 points), irregularities 
or thickening of the vessel wall (1 point), and plaques or 
stenoses (2 points). Peripheral atherosclerosis was quanti-
fied as normal ABI in rest and after exercise (0 point) or 
pathologic values of the ABI either in rest or in only after 
exercise (2 points).
Blood pressure measurements were performed in every 
patient in three different situations: (1) during the measure-
ments with the Vascular Explorer device in the early morn-
ing in rest, (2) by the nurses on the ward during the morn-
ing, and (3) right before performing the exercise ECG. The 
blood pressure regulation was classified according to the 
classification of the European Society of Cardiology [20].
Photoplethysmographic measurements
The pulse wave velocities and the augmentation indices 
as parameters for arterial stiffness were measured with the 
Vascular Explorer (Enverdis, Jena, Germany). Measure-
ments were performed after 5 min of rest in a quiet and 
temperature-controlled room in supine position. Blood 
pressure measurements and pulse wave analysis were per-
formed with photoplethysmographic sensors and inflat-
able upper arm and lower leg cuffs, registering the vol-
ume changes in the cuffs due to the pressure changes in 
the underlying arteries by the pulse waves, as described 
in detail elsewhere [21]. The ankle brachial indices (ABI) 
were calculated using the blood pressure values in the 
lower and upper extremities. The PWV and the AIX for the 
pressure curves in the central aorta were calculated with 
specific transfer functions [22, 23]. As a new function, the 
PWV and AIX for the central aorta were normalized to 
age-dependent normal values, resulting in the VA. The age-
dependent normal values for the PWVao and AIXao were 
calculated out of the data of the Anglo-Cardiff Collabora-
tive Trial (ACCT) [24]. In a final step, the differences of the 
VA to the chronological age were calculated and compared 
between the groups.
The VA was additionally determined via the charts of 
the European SCORE system [10], and differences to the 
chronological age were calculated.
The study was approved by the local ethics committee 
of the University of Jena (reference number 2691-11). All 
procedures were performed in accordance with the recom-
mendations in the Helsinki Declaration. ClinicalTrial.gov 
identifier: NCT01091194.
Statistical analysis
Continuous data are expressed as mean ± SD, and categor-
ical data are presented as counts and percentages. All data 
were analyzed using IBM® SPSS® Statistics Version 20 
(IBM Corporation). Categorical data χ2 and Fisher’s exact 
test were used. The Mann–Whitney U test was used for 
between-group comparisons. Statistical significance was 
assumed at a P < 0.05.
Results
Patients characteristics
Thirty patients (21 male, 9 female) with a mean age of 
65.3 ± 8.8 years were included into this study. The baseline 
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characteristics are summarized in Table 1. The diagnosis 
hyperlipoproteinemia was found in the list of diagnosis of 
18 patients; only 3 of these patients were on statin therapy 
at the time of admission; all of them had a hyperlipopro-
teinemia as defined in our study protocol as total choles-
terol >5 mmol/l and/or LDL >3 mmol/l. In the group of the 
other 12 patients without a former diagnosis of hyperlipo-
proteinemia, 8 patients were on statin therapy at the time of 
admission and 3 had high levels of total cholesterol and/or 
HDL measured. Of the 21 patients with measured hyperli-
poproteinemia at time of admission, 5 patients were on sta-
tin therapy.
Of the 6 patients with diabetes mellitus type 2, two 
patients were on insulin therapy. The 3 active smokers in 
our study had an acquired burden of 21.7 ± 7.7 pack-years, 
and the 7 former smokers (stopped since 23.4 ± 19.5 years) 
had an acquired burden of 16.9 ± 10.2 pack years (Table 1).
Twenty-two of the 30 patients had been on antihyperten-
sive drugs due to known arterial hypertension; 14 patients 
were on single drug treatment (8 on beta blockers, 2 on 
ACE-Inhibitors, and 4 on sartans), 6 patients on a combi-
nation of beta blockers and ACE-Inhibitors, and 5 patients 
on a combination of beta blockers and sartans. The mean 
values of the AIX were not different between the patients 
without or with regular intake of ACE inhibitors or sartans 
(AIXao 33.8 ± 11.8 vs. 33.2 ± 11.5); however, lower val-
ues were measured in the patients with high daily doses 
of the substances, i.e., 40 mg Enalapril, 10 mg Ramipril, 
32 mg Candesartan (AIXao 25.3 ± 10.1). The same ten-
dency—to a lower extent—was seen in the patients on 
beta-blockers. Due to low numbers of patients, the differ-
ences were not statistically significant.
After serial measurements of the blood pressure during 
the hospital stay, high blood pressure values were found in 
all patients, 13 patients were classified into the blood pres-
sure classes 1, 2, or 3 and another 17 patients in the blood 
pressure classes 4 and 5.
The white blood cell counts ranged from 5.000 to 
12.700/mcL (mean 7.483 ± 1.860/mcL), the eryth-
rocyte sedimentation from 1 to 81 mm/h (mean 
17.3 ± 15.8 mm/h), and the concentration of C-reactive 
protein from below the detection threshold of 2.5–48 mg/l 
(mean 4.6 ± 9.2 mg/l). Erythrocyte sedimentation after 2 h 
differed significantly between patients without and with 
atherosclerosis (p = 0.046). The concentration of C-reac-
tive protein tended to be higher in patients with atheroscle-
rosis, however, likely due to the small size of our patient 
cohort; no statistically significant difference was found. 
AIX did also not correlate with the aforementioned mark-
ers of inflammation.
Atherosclerosis of any degree was found in 24 of the 30 
patients. These were 81.0 % of the male patients and 77 % 
of the female patients.
In the analysis of the atherosclerotic pattern in the single 
patients, there was no age dependency found (Table 2), but 
the patients with atherosclerotic disease were significantly 
older compared with the patients without atherosclerotic 
lesions at any site (Table 3). Every patient above the age 
of 65 years had a positive finding of atherosclerosis at any 
localization or of any degree. 
Atherosclerosis of any degree was found in 69.2 % of 
the patients with arterial hypertension in the classes 1–3 
and in 88.2 % of the patients with arterial hypertension in 
the classes 4 and 5 (p = 0.36).
Table 1  Demographic data 
of patients with or without 
atherosclerosis of any degree 
and any localization
RR class, classification of the blood pressure regulation according to the classification of the European 
Society of Cardiology [20]. BMI body mass index, LDL low density lipoprotein
* Mann–Whitney U test
No atherosclerosis (n = 6) Atherosclerosis (n = 24) p value
Sex(% men) 66.7 70.8 1.0
RR Class (% ≤ 3) 66.7 37.5 0.360
BMI (kg/m2) 28.0 ± 5.7 28.9 ± 3.4 0.743*
Active smoker (n) 0 3 1.0
Former smoker (n) 1 6 1.0
Diabetes mellitus (n) 0 6 0.302
Cholesterol >5 mmol/l (n) 5 15 0.633
LDL >3 mmol/l (n) 4 14 1.0
Statins on admission (n) 1 10 0.372
C-reactive protein (mg/l) 2.3 ± 2.2 5.2 ± 10.3 0.218
Erythrocyte sedimentation (1 h, mm) 10.7 ± 9.2 18.6 ± 16.7 0.145
Erythrocyte sedimentation (2 h, mm) 20.5 ± 13.6 36.5 ± 22.3 0.046
White blood cell count (mcL) 8.1 ± 2.4 7.3 ± 1.7 0.476
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Augmentation index, pulse wave velocity, and vascular 
age
The underlying thesis of this study was that the normali-
zation of the measurements of PWV and AIX to the age-
dependent normal values—resulting in a new variation of 
the parameter vascular age—and calculating the difference 
between this vascular age (VA) and the chronological age 
(CA) can discriminate between patients with atheroscle-
rosis and no atherosclerosis. The measured values for the 
PWV and AIX and the deduced VA are shown in Table 3, 
resulting differences between the vascular age and the 
chronological age (ΔVA–CA) in Fig. 1. Patients with find-
ings of atherosclerosis were significantly older, as were the 
calculated VA in our study population (Table 3).
As the main finding of our pilot study, we found the vas-
cular ages, deduced from the AIXao (VA-AIXao), in the 
same range as the CA in the patients without atheroscle-
rosis (mean Δ VA-CA −1.3 ± 4.2 years), while they were 
higher in the group of patients with atherosclerosis (mean 
ΔVA–CA +23.8 ± 19.6 years). This difference between 
the groups was not significant (p = 0.09) (Fig. 1).
To discriminate if there are age-dependent differences in 
the accuracy of the parameter, we plotted the ΔVA–CA for 
every single patient against the CA: in the patients above 
65 years, the parameter VA-AIXao did not reflect the vas-
cular status of the patients: the ΔVA–CA were dispersed 
between −29.6 and +30.5 years, although all these patients 
had atherosclerotic findings. This was different for the 
patients below 65 years: in those with atherosclerosis (mean 
Table 2  Degree and 
localization of atherosclerosis 
of all patients, sorted according 
to the chronological age
Italic values: irregularities or thickening of the vessel wall (1 point). Bold values: plaques or stenoses (2 
points). bold–italic values: pathologic ABI measurement (2 points). RR class, classification of the blood 
pressure regulation according to the classification of the European Society of Cardiology [20]








Arterial disease of 
any degree
43.6 0 0 0 0 No
51.2 0 0 2 2 Yes
52.4 0 0 0 0 No
55.2 0 0 0 0 No
58.2 0 1 0 1 Yes
58.2 0 1 0 1 Yes
59.2 0 0 0 0 No
59.2 2 2 0 4 Yes
59.2 1 2 2 5 Yes
59.4 2 2 0 4 Yes
61.4 2 0 0 2 Yes
62.5 2 0 2 4 Yes
62.9 0 0 0 0 No
63.0 0 0 0 0 No
63.5 1 2 0 3 Yes
64.7 2 2 2 6 Yes
68.4 0 1 0 1 Yes
69.5 1 2 0 3 Yes
70.1 0 2 0 2 Yes
70.6 0 1 0 1 Yes
71.2 2 2 0 4 Yes
72.3 0 2 0 2 Yes
72.3 1 2 0 3 Yes
73.3 0 2 0 2 Yes
74.8 1 2 0 3 Yes
75.0 0 2 0 2 Yes
76.9 0 1 0 1 Yes
77.0 0 2 0 2 Yes
77.0 2 1 0 3 Yes
77.3 1 2 2 5 Yes
256 Heart Vessels (2017) 32:252–259
1 3
age 59.8 ± 3.8 years)—except two—the mean calculated 
VA-AIXao was with 83.0 ± 20.0 significantly higher than 
the CA, while in the patients without atherosclerosis (mean 
age 56.0 ± 7.4 years), the VA was on the same level (mean 
VA-AIXao 54.7 ± 8.2) of the CA (Fig. 2). Comparing the 
ΔVAao-CA of the patients <65 years with atherosclerosis 
with these of the patients without atherosclerosis, a p value 
of p = 0.036 was calculated.
The other variations of the vascular age (VA-PWVao and 
VA-ESC) did not differentiate between the patient groups.
The same comparisons had been made for the patients 
in lower vs. higher RR classes. The CA of the patients 
did not differ comparing the groups, but we did find sig-
nificantly higher augmentation indices (AIXao) and pulse 
wave velocities (PWVao), as well as higher vascular ages 
in the patients with higher blood pressure values (Table 4). 
The VA-AIXao were found in the same range as the CA 
in the patients in lower RR classes (mean ΔVA–CA 
+3.0 ± 17.2 years), while they were significantly higher in 
the group of patients in the higher RR classes (mean ΔVA–
CA +20.0 ± 21.5 years) (Fig. 3).
Discussion
In our pilot study, the calculation of the vascular age by 
normalization of the augmentation index AIXao with age-
dependent normal values allowed the screening for vascu-
lar changes due to arterial hypertension or atherosclerotic 
changes, for the latter with the highest diagnostic yield in 
individuals at or below the age of 65 years. Since both, ath-
erosclerosis and high blood pressure increase the cardio-
vascular risk and these measurements can be done noninva-
sively with portable devices, this screening method seems 
to be suitable for screening programs for primary preven-
tion of cardiovascular events, i.e., in occupational health 
screening programs.
Table 3  Results of the measurements with the Vascular Explorer and 
calculations of the vascular age using several formulas in patients 
with or without atherosclerosis at any localization and of any degree
PWVao, pulse wave velocity in the central aorta, AIXao, augmenta-
tion index in the central aorta, VA-ESC, vascular age determined via 
the charts of the European SCORE system [10], VA-PWVao, vascular 
age calculated from the PWVao and the data of the ACCT [24], VA-







Age 56.0 ± 7.4 67.6 ± 7.6 0.006
PWVao 7.84 ± 0.88 8.60 ± 1.55 0.173
AIXao 24.00 ± 7.04 35.83 ± 10.45 0.021
VA-ESC 69.5 ± 11.55 80.38 ± 7.26 0.025
VA-PWVao 56.29 ± 7.63 64.7 ± 10.1 0.049
VA-AIXao 54.73 ± 8.18 82.86 ± 21.40 0.012
Fig. 1  Differences between the patients’ chronological age and the 
calculated vascular ages in years (ys) in patients with or without ath-
erosclerosis. VA-PWVao, vascular age calculated from the PWVao 
and the data of the ACCT [24]. VA-AIXao, vascular age calculated 
from the AIXao and the data of the ACCT [24]. VA-ESC, vascular age 
determined via the charts of the European SCORE system [10]
Fig. 2  Differences between the calculated vascular age (VA-AIXao) 
and the patients’ chronological age, plotted against the chronological 
age in years in patients with or without atherosclerosis. VA-AIXao, 
vascular age calculated from the AIXao and the data of the ACCT 
[24]
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It has been shown that the intake of beta blockers, ACE 
inhibitors, and angiotensin-1-receptor-antagonists reduces 
the measured augmentation index in patients with stages I 
and II arterial hypertension as well as in a variety of other 
indications [25, 26]. These effects could be shown in our 
data concerning high doses of ACE inhibitors and angio-
tensin-receptor antagonists. However, the most effective 
reduction of the AIX has been recorded when the therapeu-
tic goal of low blood pressure values had been reached.
In our study, the measurements of the PWV and AIX, as 
well as the calculation of the VA, were done with the Vas-
cular Explorer. In a study comparing the Vascular Explorer 
with the SphygmoCor (Atcor Medical, Sydney, Australia) 
and the Arteriograph (TensioMed, Budapest, Hungary), two 
other devices for plethysmographic measurements of PWV 
and AIX, there were no significant differences concerning the 
values of the measured PWV in repetitive measurements in 
44 individuals. The AIX was measured at a higher level with 
the SphygmoCor compared to Arteriograph and Vascular 
Explorer, while the results were comparable among the latter 
devices. Measurements with the Vascular Explorer gave com-
parable results in the sitting and supine position [21].
The source of the age-dependent normal values that were 
used for the calculation of the vascular age in this study had 
been the database of the Anglo-Cardiff Collaborative Trial 
(ACCT). In this population study, over 10.000 randomly 
selected individuals from East Anglia and Wales had been 
examined. For the determination of the age related changes 
of the AIX and PWV, the data of individuals with diabetes, 
arterial hypertension, renal disease, or cardiovascular dis-
ease had been excluded. Finally, the data of 4.001 healthy 
individuals had been analyzed. The PWV and the AIX had 
been measured in ACCT with the SphygmoCor device in 
a sitting position; the results were grouped by gender and 
decade of age. Nearly two-thirds of this study population 
was between 40 and 69 years old, 14 % were in the eighth 
decade and only 2 % (77 individuals) in the ninth decade. 
Consecutively, the calculated normal values for the PWV 
and AIX for the older people are based on a smaller num-
ber of individuals [24].
In our pilot study, the age-dependent normal values of 
these healthy individuals were used for the first time to our 
knowledge to calculate the vascular age (VA) in patients 
with suspicion for coronary heart disease. These patients 
were extensively screened for findings of atherosclerosis.
The VA derived from the AIXao could discriminate 
very well between patients with or without atherosclerosis, 
either in the coronary arteries, the extracranial arteries, or 
in the peripheral arteries of the lower extremity in patients 
between 40 and 65 years of age, the typical age for occupa-
tional health screening programs.
Our pilot study has some limitations. The most important 
is the limited number of included patients. Another limita-
tion is the distribution of age and atherosclerotic findings in 
our study population. All our patients above 65 years of age 
had atherosclerotic findings in at least one area.
Conclusions
In summary, we found that in this pilot study, the param-
eters VA-AIXao have a very promising candidate for 
Table 4  Results of the measurements with the Vascular Explorer and 
calculations of the vascular age using several formulas in patients 
with RR Classes ≤3 or ≥4
RR classes, classification of the blood pressure regulation accord-
ing to the classification of the European Society of Cardiology [20]. 
PWVao, pulse wave velocity in the central aorta, AIXao, augmenta-
tion index in the central aorta, VA-ESC, vascular age determined via 
the charts of the European SCORE system {}. VA-PWVao, vascular 
age calculated from the PWVao and the data of the ACCT [24]. VA-
AIXao, vascular age calculated from the AIXao and the data of the 
ACCT [24]
RR classes ≤3  
(n = 13)
RR Classes ≥4 
(n = 17)
p value
PWVao 8.03 ± 1.21 8.79 ± 1.60 0.02
AIXao 26.92 ± 7.65 38.47 ± 10.45 0.002
Age 63.0 ± 11.0 67.07 ± 8.78 0.363
VA-ESC 73.23 ± 10.66 82.0 ± 5.68 0.015
VA-PWVao 58.83 ± 10.61 66.61 ± 8.4 0.061
VA-AIXao 66.01 ± 22.18 86.45 ± 20.53 0.017
Fig. 3  Differences between the patients’ chronological age and 
the calculated vascular ages in years in patients in lower or higher 
blood pressure classes. VA-PWVao, vascular age calculated from the 
PWVao and the data of the ACCT [24]. VA-AIXao, vascular age cal-
culated from the AIXao and the data of the ACCT [24]. VA-ESC, vas-
cular age determined via the charts of the European SCORE system 
[10]
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screening programs for atherosclerosis, i.e., in occupational 
health screening programs. This result of our pilot study 
has to be confirmed in a larger study population.
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